A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study
Tanguy Y. Seiwert, Sara Kochanny, Kevin Wood, Francis P. Worden, Douglas Adkins, James L. Wade, Bethany G. Sleckman, Daniel Anderson, Ryan J. Brisson, Theodore Karrison, Walter M. Stadler, Everett E. Vokes
Dive into the research topics of 'A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study'. Together they form a unique fingerprint.